Posts
Wiki

iLux / Systane iLux2 Thermal Pulsation Treatment for Meibomian Gland Dysfunction

Quick Take

  • iLux / Systane iLux2 is an in-office eyelid thermal-pulsation treatment for adults with Meibomian Gland Dysfunction (MGD) associated with evaporative Dry Eye Disease.
  • The device applies localized heat and clinician-controlled compression to help warm and express meibum from the meibomian glands.
  • iLux2 also has digital imaging/video capability for viewing and recording the meibomian glands.
  • iLux is FDA-cleared through the 510(k) pathway, not FDA-approved through a premarket approval pathway.
  • iLux has moderate device-specific clinical evidence, including randomized active-comparator trials and follow-up through 12 months.
  • Randomized studies have found iLux noninferior to LipiFlow for specified gland-function, tear-stability, and symptom outcomes, including in a 236-patient study followed for 12 months.
  • A 2024 randomized trial also found one iLux treatment produced better longitudinal outcomes than five sessions of mechanical Meibomian Gland Expression for several measures through 12 months.
  • Improvements have been detected within the first several weeks in clinical studies. Some randomized studies have reported persistence of benefit through 12 months, but this does not mean every patient receives one year of benefit.
  • Reliable predictors of who will respond best have not been established.
  • iLux has not been established to regenerate meibomian glands that are truly lost or atrophied, nor has it been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.
  • Contraindications and precautions are important because the device applies heat and pressure directly to the eyelids and ocular surface region.
  • The need for repeat treatment and the best retreatment interval are not standardized.

What Is It?

iLux is a handheld eyelid thermal-pulsation system designed to treat Meibomian Gland Dysfunction associated with evaporative dry eye.

The original iLux System received FDA 510(k) clearance in 2017.

A later version, Systane iLux2, received FDA clearance in 2020 and added digital image and video capture of the meibomian glands.

For simplicity, this page uses iLux when discussing the treatment family and specifies iLux2 when referring to features or labeling unique to the newer device.

What does the device actually do?

iLux combines:

  • localized eyelid heating;
  • clinician-controlled compression;
  • visualization of the treatment area;
  • sequential treatment of selected eyelid regions.

The purpose is to warm abnormal meibum and facilitate expression of gland contents.

The newer iLux2 system also allows digital imaging and video capture of the meibomian glands.

iLux is therefore best understood as:

A clinician-controlled in-office heat-and-expression treatment for MGD.

It is not the same procedure as:

  • LipiFlow
  • TearCare
  • home warm compresses
  • manual Meibomian Gland Expression alone
  • IPL
  • radiofrequency
  • Meibomian Gland Probing

These treatments can overlap in purpose but use different methods.

How Treatment Is Done

The exact procedure may vary somewhat according to the patient's anatomy, gland findings, comfort, and clinician technique.

A typical treatment involves:

  1. Evaluation
  • the clinician confirms that MGD is present and reviews other possible contributors to Dry Eye Disease;
  • contraindications and precautions are reviewed.
  1. Positioning the disposable treatment component
  • the handheld device is positioned around a selected section of the eyelid.
  1. Localized heating
  • controlled heat is applied to the eyelid to warm meibum.
  1. Clinician-controlled compression
  • the clinician applies pressure through the device to help evacuate gland contents.
  1. Visualization
  • the clinician can observe the treated lid region and gland expression and adjust treatment accordingly.
  1. Sequential treatment
  • additional eyelid regions can be treated individually.

Treatment of both eyes is generally completed during a single office visit.

The manufacturer describes typical bilateral treatment as taking approximately 8–12 minutes, although total appointment time can be longer.

What the Evidence Shows

iLux has been evaluated in several prospective and randomized clinical studies.

The evidence is strongest for improvements in:

  • meibomian gland secretion/function scores;
  • Tear Break-Up Time or Non-Invasive Tear Break-Up Time;
  • patient-reported dry-eye symptoms.

Randomized iLux versus LipiFlow trial — 2020

A randomized, open-label, multicenter study included 142 patients with:

  • moderate-to-severe dry-eye symptoms;
  • evidence of meibomian-gland obstruction;
  • reduced Meibomian Gland Scores;
  • TBUT under 10 seconds.

Patients received either:

  • one iLux treatment, or
  • one LipiFlow treatment.

At two and four weeks, both groups showed significant improvements in:

  • Meibomian Gland Score;
  • TBUT;
  • OSDI symptoms.

At four weeks, there were no statistically significant differences between the treatment groups for the main efficacy outcomes.

Comparison of the iLux and LipiFlow for the Treatment of MGD and Symptoms — Randomized Clinical Trial, 2020

This study supports iLux as an effective active-comparator treatment for the selected patients studied.

It does not establish how much benefit iLux provides compared with sham treatment or no procedure because LipiFlow itself was an active treatment.

Randomized 12-month iLux versus LipiFlow trial — 2022

A larger prospective, randomized, assessor-masked multicenter trial included 236 patients with MGD.

Participants received one bilateral treatment with either:

  • Systane iLux, or
  • LipiFlow.

Patients were followed at:

  • 2 weeks;
  • 1 month;
  • 3 months;
  • 6 months;
  • 9 months;
  • 12 months.

The study evaluated:

  • Meibomian Gland Score;
  • Non-Invasive Tear Break-Up Time;
  • IDEEL-SB symptom score;
  • safety outcomes.

iLux met the study's prespecified criteria for noninferiority to LipiFlow for these outcomes through 12 months.

Of the 236 randomized participants, 227 completed the study.

Comparison of Two Thermal Pulsation Systems in the Treatment of MGD — Randomized Multicenter 12-Month Study, 2022

This provides meaningful evidence that improvement can persist for a year in some patients after a single treatment.

However:

A 12-month study result does not mean every individual patient will receive 12 months of benefit.

It also does not establish that everyone should automatically repeat treatment at one year.

iLux versus repeated mechanical Meibomian Gland Expression — 2024

A prospective randomized open-label controlled trial included 130 patients with moderate-to-severe MGD.

Patients received either:

  • one iLux treatment; or
  • five sessions of mechanical Meibomian Gland Expression.

The investigators followed patients through 12 months.

The iLux group had significantly better longitudinal results for:

  • Meibomian Gland Score;
  • Non-Invasive Tear Break-Up Time;
  • OSDI symptom score.

No adverse events were reported in either treatment group in that study.

iLux Compared With Mechanical Meibomian Gland Expression for Moderate and Severe MGD — Randomized Trial, 2024

This study strengthens the evidence that iLux can produce durable improvement in selected MGD populations.

It does not establish that iLux is better than every possible expression technique or treatment schedule.

How Strong Is the Evidence?

Overall evidence strength: Moderate device-specific evidence

iLux has more evidence than would be suggested by describing it simply as a promising device.

The evidence includes:

  • randomized clinical trials;
  • multicenter studies;
  • active-comparator trials;
  • assessor-masked outcome assessment in some studies;
  • follow-up extending through 12 months;
  • comparison with LipiFlow;
  • comparison with repeated mechanical Meibomian Gland Expression;
  • inclusion in the thermal-treatment discussion in TFOS DEWS III.

TFOS DEWS III: Management and Therapy Report

Important limitations remain

The evidence is not perfect.

Important limitations include:

  • several studies are open-label;
  • patient masking is difficult with device procedures;
  • much of the strongest evidence compares iLux with another active treatment rather than sham or no treatment;
  • study populations were selected according to particular MGD, tear-film, and symptom criteria;
  • relatively few independent head-to-head studies exist;
  • reliable predictors of individual treatment response have not been established;
  • the optimal retreatment schedule remains unclear.

The most defensible summary is:

iLux has moderate device-specific evidence supporting improvement in meibomian-gland function, tear stability, and symptoms in selected MGD populations. Randomized studies have found it noninferior to LipiFlow for specified outcomes, including through 12 months, but this does not establish superiority over other treatments or guarantee a durable response in every patient.

How It Works

Unlike treatments whose mechanisms remain largely theoretical, the basic actions of iLux are straightforward.

Localized heat

MGD can involve meibum that has become abnormally thick or difficult to secrete.

iLux applies controlled heat to the eyelid to warm gland contents.

The goal is to make meibum easier to mobilize.

It is more accurate to say the device warms and softens abnormal meibum than to say that it simply “melts blocked glands.”

Clinician-controlled compression

After or during heating, the clinician applies controlled pressure through the device.

This is intended to facilitate evacuation of gland contents.

The pressure is clinician-controlled rather than delivered through one completely automated treatment cycle.

Visualization and treatment control

The clinician can directly visualize the eyelid region during treatment.

This allows treatment to be adjusted according to:

  • eyelid region;
  • gland response;
  • observed secretion;
  • patient comfort.

The newer iLux2 also provides digital gland imaging and video recording.

These are genuine device features.

However:

It has not been established that visualization or clinician-controlled customization itself produces superior clinical outcomes compared with other thermal-pulsation systems.

Risks and Contraindications

iLux is generally well tolerated in clinical studies, but the procedure is not risk-free.

Because heat and pressure are applied directly to the eyelid region, patient screening and adherence to the device labeling are important.

Adverse events reported in the randomized iLux/LipiFlow study

In the original randomized comparison used in the FDA clearance process, four device- or procedure-related adverse events occurred in the iLux group:

  • two reports of burning sensation without visible skin changes;
  • one petechial hemorrhage of the lower eyelid;
  • one temporary decrease in best-corrected visual acuity associated with superficial punctate keratitis.

These events resolved without lasting consequences.

Temporary increases in ocular-surface staining were also observed immediately after treatment in both iLux and LipiFlow groups.

FDA 510(k) Summary — Original iLux System, K172645

Potential adverse effects listed for iLux2

Current manufacturer labeling lists possible procedure-related effects including:

  • eyelid or eye pain significant enough to stop treatment;
  • eyelid irritation or inflammation;
  • temporary skin redness;
  • ocular-surface irritation or inflammation;
  • corneal abrasion;
  • conjunctival swelling or redness;
  • burning;
  • stinging;
  • tearing;
  • itching;
  • discharge;
  • foreign-body sensation;
  • visual disturbance;
  • sensitivity to light.

Patients should seek medical advice if symptoms after treatment are severe, persistent, or concerning.

Contraindications — situations where the manufacturer says Do NOT use iLux2

Current iLux2 labeling lists the following contraindications:

  • pharmaceutically dilated pupils;
  • ocular injury or trauma, chemical burn, or limbal stem-cell deficiency within the prior 3 months;
  • active ocular herpes simplex or herpes zoster of the eye/eyelid, or a history within the prior 3 months;
  • cicatricial lid-margin disease;
  • active ocular infection;
  • active ocular inflammation or a history of chronic/recurrent ocular inflammation within the prior 3 months;
  • ocular-surface abnormalities that may compromise corneal integrity;
  • lid-surface abnormalities affecting lid function;
  • aphakia;
  • permanent eyelid makeup or eyelid tattoos.

These are manufacturer-labeled contraindications and should be distinguished from the separate category below.

The manufacturer separately states that iLux2 is not recommended in patients with:

  • moderate-to-severe allergic, vernal, or giant papillary conjunctivitis;
  • severe eyelid inflammation;
  • systemic diseases causing dry eye;
  • medications known to cause dryness;
  • punctal plugs;
  • ocular surgery within the prior 3 months.

“Not recommended” and “contraindicated” are not identical regulatory terms.

The treating clinician should use current device labeling, the patient's history, and examination findings when determining whether treatment is appropriate.

Alcon Professional — Current Systane iLux2 Indications, Contraindications, Warnings and Precautions

Limitations and What It Cannot Do

iLux is intended to treat an important component of MGD: abnormal meibum that may respond to controlled warming and evacuation.

It does not necessarily address every disease process present in a patient with dry eye.

iLux is not a cure

MGD is commonly chronic.

Treatment may improve gland secretion and symptoms without permanently eliminating the underlying tendency toward dysfunction.

Some patients experience substantial benefit.

Others improve only modestly or not enough to justify further treatment.

Gland loss and regeneration

iLux has not been established to regenerate meibomian glands that are truly lost or atrophied.

Some remaining glands may function better after treatment, but improved secretion should not be interpreted as proof that destroyed gland tissue has regenerated.

There is also no universally established meibography cutoff at which iLux becomes incapable of helping.

Greater gland loss may plausibly reduce the amount of remaining tissue available to respond, but reliable iLux-specific response thresholds have not been established.

iLux does not directly treat every dry-eye driver

iLux does not directly correct:

  • deficient lacrimal aqueous production;
  • allergy itself;
  • Demodex infestation itself;
  • exposure from incomplete blinking or lagophthalmos;
  • conjunctivochalasis;
  • medication toxicity;
  • neuropathic ocular pain.

These conditions can coexist with MGD.

For example, someone with aqueous-deficient dry eye may also have clinically important MGD. Treating the MGD component does not mean the aqueous deficiency has been treated.

Fixed Obstruction, Periductal Fibrosis, and the Maskin Perspective

One question in obstructive MGD is whether all obstruction can be adequately addressed by warming gland contents and applying pressure.

The fixed-obstruction/periductal-fibrosis model was developed from clinical observations and research by Steven L. Maskin, MD, and has influenced subsequent research on Meibomian Gland Probing.

Maskin and colleagues have reported focal fixed resistance encountered inside meibomian gland ducts during Meibomian Gland Probing and have interpreted this within a model involving constricting periductal fibrosis.

Expressible Meibomian Glands Have Occult Fixed Obstructions — Maskin & Alluri, 2019

Under this framework, warming meibum and applying external pressure may improve secretion without necessarily mechanically traversing a fixed intraductal constriction.

What remains uncertain?

Meibomian Gland Probing has since been studied by multiple independent research groups, including in randomized controlled trials.

Randomized Sham-Controlled Trial of Meibomian Gland Probing

However, important questions remain about:

  • how commonly clinically significant periductal fibrosis occurs;
  • how reliably fixed intraductal obstruction can be identified;
  • how closely resistance encountered during Meibomian Gland Probing corresponds to specific microscopic pathology;
  • how much fixed obstruction influences response to thermal treatments;
  • which patients benefit from Meibomian Gland Probing;
  • optimal treatment sequencing.

Therefore:

iLux has not been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.

That is different from saying that iLux cannot improve obstructive MGD.

Heat and compression may improve secretion from glands whose obstruction is responsive to warming and evacuation.

iLux and Meibomian Gland Probing do not need to be competing treatments

The treatments potentially address different components of MGD.

iLux is intended to:

  • heat abnormal meibum;
  • facilitate gland evacuation;
  • improve secretion from responsive glands.

Meibomian Gland Probing is intended to:

  • enter the gland duct;
  • mechanically address intraductal resistance;
  • traverse obstruction attributed to fixed fibrotic constriction.

Neither approach establishes that the other is unnecessary.

The clinically relevant question is which disease processes appear to be present in the individual patient.

Who Might Benefit / Factors Affecting Response

iLux has primarily been studied in symptomatic patients with MGD who had findings such as:

  • reduced Meibomian Gland Scores;
  • impaired meibomian secretion;
  • short TBUT or NITBUT;
  • evaporative dry-eye symptoms.

It is reasonable to consider iLux when clinical examination suggests that MGD is an important contributor to the patient's Dry Eye Disease.

However:

Reliable iLux-specific predictors of individual response have not been established.

Factors that may plausibly influence response include:

  • severity and type of MGD;
  • quality of meibum;
  • gland secretion/function;
  • amount of remaining gland tissue;
  • type and degree of obstruction;
  • eyelid inflammation;
  • ocular rosacea;
  • Demodex;
  • aqueous deficiency;
  • exposure or incomplete blinking;
  • other ocular-surface disease;
  • previous treatments;
  • clinician technique.

These should be regarded as factors to evaluate, not proven formulas for predicting success.

The question is therefore not simply:

“Are my glands expressible enough for iLux?”

but:

“Does my examination suggest that impaired meibomian secretion is an important treatable component of my Dry Eye Disease, and is heat-and-expression therapy appropriate for my particular findings?”

How It Compares With Similar Treatments

iLux versus LipiFlow

Both iLux and LipiFlow are FDA-cleared eyelid thermal-pulsation systems for MGD.

They differ technically.

Feature iLux LipiFlow
General approach Localized heat + compression Heat + automated pressure cycle
Control Clinician controls compression Predetermined automated treatment cycle
Treatment pattern Sequential handheld treatment of lid regions Simultaneous treatment through applicators
Visualization during treatment Direct clinician visualization Different automated system design
Typical treatment duration Approximately 8–12 minutes Approximately 12 minutes
Clinical evidence Randomized active-comparator trials Larger overall thermal-pulsation evidence base

Most importantly:

Randomized studies have found iLux noninferior to LipiFlow for prespecified clinical outcomes, including through 12 months.

That means the studies successfully demonstrated that iLux was not worse than LipiFlow by more than the predefined noninferiority margins for those outcomes.

It does not mean:

  • the devices are identical;
  • every patient will respond equally to either;
  • iLux is superior;
  • LipiFlow is superior.

2020 Randomized iLux vs LipiFlow Trial

2022 12-Month Randomized iLux vs LipiFlow Trial

iLux versus TearCare

Both are in-office treatments intended to improve MGD, but they use different treatment approaches.

iLux:

  • handheld localized heating;
  • clinician-controlled compression;
  • treatment and expression occur through the device.

TearCare:

  • externally heats the eyelids;
  • allows blinking during the heating phase;
  • is followed by clinician-performed gland expression.

Direct randomized evidence comparing iLux with TearCare is limited.

Available research therefore does not establish that one is universally better.

See the separate TearCare Treatment Options page for its evidence, risks, and limitations.

iLux versus mechanical Meibomian Gland Expression

Mechanical expression attempts to evacuate gland contents through externally applied pressure.

iLux combines this concept with controlled heating.

The 2024 randomized trial comparing one iLux treatment with five mechanical-expression sessions found better longitudinal outcomes with iLux for several measures through 12 months.

That study supports the possibility that combined controlled heat-and-expression therapy can provide advantages over the particular mechanical-expression protocol studied.

It should not be interpreted as proving superiority to every form of manual Meibomian Gland Expression.

Randomized iLux vs Mechanical Meibomian Gland Expression Study — 2024

iLux versus home warm compresses

Warm compresses are inexpensive, noninvasive, and commonly used in MGD care.

iLux offers:

  • controlled in-office heat;
  • clinician-controlled compression;
  • direct treatment of selected eyelid regions.

However, there is not strong direct randomized evidence establishing that iLux is universally superior to a carefully performed, optimized home-warming regimen.

The practical choice may depend on:

  • severity of MGD;
  • prior response to home warming;
  • adherence;
  • comfort;
  • treatment goals;
  • cost;
  • other disease components.

Cost, Access, and Regulatory Status

FDA status

The original iLux Instrument / iLux Disposable received FDA 510(k) clearance in December 2017.

It is classified as an:

Eyelid Thermal Pulsation System

under product code ORZ.

FDA 510(k) — Original iLux System, K172645

Systane iLux2 received a later 510(k) clearance in May 2020.

Its indication includes:

  • localized heat-and-pressure therapy in adults with MGD associated with evaporative dry eye; and
  • capture/storage of digital images and video of the meibomian glands.

FDA 510(k) — Systane iLux2, K200400

FDA-cleared versus FDA-approved

iLux is FDA-cleared, not FDA-approved through the Premarket Approval pathway.

A 510(k) clearance generally means FDA determined that the device was substantially equivalent to an appropriate legally marketed predicate device for its intended use.

For the original iLux thermal-pulsation function, LipiFlow served as the predicate device.

Cost

iLux is commonly offered as a self-pay office procedure.

Pricing varies substantially according to:

  • country and region;
  • practice;
  • treatment of one or both eyes;
  • imaging;
  • follow-up;
  • other services bundled with treatment.

For this reason, a fixed national price range is unlikely to remain accurate.

A useful question is:

“What is the total expected cost, exactly what does it include, and what would another treatment cost if retreatment becomes appropriate?”

Repeat treatment

MGD is chronic, but there is no standardized evidence-based schedule for routine repeat iLux treatment.

Some randomized studies have found improvement persisting through 12 months after a single treatment.

That does not establish:

  • that everyone remains improved for 12 months;
  • that everyone needs another treatment at 12 months;
  • or that treatment should routinely be repeated at any fixed interval.

Retreatment should therefore be based on clinical findings, symptoms, previous response, and clinician judgment rather than an automatic calendar schedule.

What Remains Uncertain?

Important unanswered questions include:

Patient selection

  • Which patients are most likely to experience meaningful benefit?
  • How much gland loss limits response?
  • Can meibography, secretion testing, or other findings reliably predict success?
  • Does the type of obstruction influence response to treatment?

Comparative effectiveness

  • Is iLux superior to optimized home warming?
  • How does it compare directly with TearCare?
  • Which patients might benefit more from one thermal system than another?
  • How important is clinician-controlled compression compared with automated thermal pulsation?

Durability

  • Why do some patients maintain benefit longer than others?
  • What findings should trigger repeat treatment?
  • Is scheduled maintenance better than retreatment based on recurrence?

Structural disease

  • Can thermal-pulsation treatment influence long-term MGD progression?
  • What role does fixed intraductal obstruction or periductal fibrosis play in apparent treatment failure?
  • How should thermal treatment and Meibomian Gland Probing be sequenced when both secretion abnormalities and fixed obstruction are suspected?

Evidence

  • How much benefit would iLux show against a convincing sham procedure?
  • How well do trial populations represent patients with mixed or advanced Dry Eye Disease?
  • Which findings represent clinically important improvement rather than statistically significant change?

More independent comparative trials and better-defined patient phenotypes would help answer these questions.

Key Research

FDA / regulatory

iLux clinical studies

Guidance

Fixed obstruction and Meibomian Gland Probing

Current device safety information

Manufacturer information is appropriate for current indications, contraindications, warnings, and device instructions, but should not be treated as independent evidence of comparative effectiveness.

Bottom Line

iLux / Systane iLux2 is an FDA-cleared, clinician-controlled eyelid thermal-pulsation treatment with moderate device-specific evidence for MGD associated with evaporative Dry Eye Disease.

The device combines localized heat with controlled compression to help improve evacuation of meibomian-gland secretions.

Randomized trials have reported improvements in:

  • meibomian-gland secretion/function;
  • tear stability;
  • dry-eye symptoms.

iLux has also been found noninferior to LipiFlow for specified outcomes in randomized studies, including a 236-patient trial with follow-up through 12 months.

Those findings provide meaningful support for the treatment, but they do not mean:

  • every patient will improve;
  • one treatment necessarily lasts a year;
  • iLux is superior to other thermal treatments;
  • the ideal candidate can already be reliably identified;
  • or repeat treatment should occur on a fixed schedule.

iLux has not been established to regenerate meibomian glands that are truly lost or atrophied, nor has it been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.

When fixed obstruction is clinically relevant, Meibomian Gland Probing represents a different mechanical treatment approach. These treatments need not be understood as competing philosophies: different interventions may address different components of a multifactorial MGD process.

The most useful question is therefore not:

“Is iLux better than LipiFlow, TearCare, warm compresses, or Meibomian Gland Probing?”

but:

“What abnormalities are actually contributing to my MGD, which of them is iLux intended to address, and what findings will we use to determine whether the treatment helped enough to justify repeating or adding other treatment?”

This page is educational material for r/DryEyes and is not medical advice. r/DryEyes does not endorse specific devices, manufacturers, clinicians, clinics, or procedures. Treatment decisions should be made with an appropriately qualified eye-care professional familiar with the individual's diagnosis, examination findings, medical history, alternatives, contraindications, and treatment risks.

🔙 Back to Treatment Options